Results 141 to 150 of about 15,740 (203)

Regional Standardization of CLL Management: Results of a Delphi Consensus Process

European Journal of Haematology, Volume 117, Issue 2, Page 442-447, August 2026.
ABSTRACT The therapeutic landscape of chronic lymphocytic leukemia (CLL) has been profoundly transformed by the introduction of Bruton tyrosine kinase and BCL‐2 inhibitors. Despite improved survival outcomes, treatment selection remains complex, particularly in older patients with comorbidities, frailty, and increased infectious vulnerability.
Enrica Antonia Martino, Annalisa Chiarenza, Salvatrice Mancuso, Marco Rossi, Caterina Stelitano, Ignazio Abbene, Sergio Cabibbo, Daniele Caracciolo, Emilia Cotzia, Amalia Figuera, Antonino Greco, Vanessa Innao, Luciano Levato, Carla Marino, Giuseppe Mineo, Laura Nocilli, Giuseppa Penna, Marika Porrazzo, Giorgio Tona, Ernesto Vigna, Fortunato Morabito, Daniela D'Angela, Massimo Gentile   +22 more
wiley   +1 more source

A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial. [PDF]

Cancers (Basel)
Pirosa MC, Hess D, Krasniqi F, Novak U, Mach N, Zenz T, Holer L, Cascione L, Cannas E, Rinaldi A, Schär S, Zucca E, Bertoni F, Stathis A, Swiss Group for Clinical Cancer Research SAKK.   +14 more
europepmc   +1 more source

BCL‐2 and MCL1 co‐inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A‐rearranged acute lymphoblastic leukaemia

British Journal of Haematology, Volume 209, Issue 2, Page 786-792, August 2026.
Mawar Karsa, Ayu Karsa, Dayna Spurling, Lin Xiao, Emma Ronca, Angelika Bongers, Weiman Gao, Andrew J. Gifford, Ali El‐Ayoubi, Laurence C. Cheung, Rishi S. Kotecha, Richard B. Lock, Charis E. Teh, Guillaume Lessene, Murray D. Norris, Andrew Wei, Michelle Haber, Michelle J. Henderson, Donia M. Moujalled, Klaartje Somers   +19 more
wiley   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, Volume 117, Issue 2, Page 320-337, August 2026.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

Integrating ex vivo drug sensitivity and genetic mutation analysis improves prediction of chemotherapy response in acute myeloid leukemia. [PDF]

Funct Integr Genomics
Li W, Ji M, Li W, Zhou Y, Jia R, Wen X, Jin S, Hao Y, Dai M, Xu S, Zhou Q, Jiang H, Ji C, Ye J.   +13 more
europepmc   +1 more source

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study

British Journal of Haematology, Volume 209, Issue 2, Page 734-739, August 2026.
Michael Wang, Wojciech Jurczak, Marek Trneny, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary‐Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer‐Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam   +18 more
wiley   +1 more source

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update

Internal Medicine Journal, Volume 56, Issue 8, Page 1421-1428, August 2026.
Abstract In 2023, a consensus statement on the diagnosis and management of chronic lymphocytic leukaemia (CLL) in Australasia was published. Since then, advances in clinical evidence and increased availability of molecular diagnostics and targeted therapies have further influenced contemporary CLL management.
Sean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, Rory Bennett, Giles Best, Nicole Chia, Tara Cochrane, Kyle Crassini, Gavin Cull, Pietro Di Ciaccio, Pasquale Fedele, Rosemary Harrup, Sharon Jackson, Bryone Kuss, Masa Lasica, Denise Lee, Thomas Lew, Paula Marlton, Monique Menzies Wojtowicz, Stephen Opat, Sumita Ratnasingam, John Francis Seymour, Dipti Talaulikar, Constantine Si Lun Tam, Robert Weinkove, Joel Wight, Stephen Mulligan, Mary Ann Anderson   +27 more
wiley   +1 more source

Case Report: Iliac perivascular myeloid sarcoma presenting with iliofemoral deep vein thrombosis and hydronephrosis. [PDF]

Front Oncol
Shan Z, Wang Y, Wang H, He J, Cai H.
europepmc   +1 more source

Anaphylactic transfusion reaction to group B platelets related to alpha‐gal syndrome: A case report

Transfusion, Volume 66, Issue 8, Page 1690-1693, August 2026.
Abstract Background Alpha‐gal syndrome (AGS), a distinct form of IgE‐mediated hypersensitivity to the carbohydrate galactose‐α‐1,3‐galactose (α‐Gal), typically occurs after repeated tick bites and leads to allergic reactions after ingestion of mammalian meat.
Oscar Andre Hinojosa, Amitava Dasgupta, Zhan Ye   +2 more
wiley   +1 more source

Rosuvastatin enhances the efficacy of venetoclax-azacitidine in older acute myeloid leukemia patients via reducing T-cell exhaustion. [PDF]

Cancer Immunol Immunother
Zhai Y, Yu Y, Bao R, Liu J, Fang J, Lu W, Zhang D, Guo H, Yao Y, Shi J.   +9 more
europepmc   +1 more source